#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Behcet's syndrome Osteosarcoma metastatic Oesophageal squamous cell carcinoma stage III Congenital myopathy Short stature homeobox gene mutation Ductal adenocarcinoma of pancreas Hepatitis D Phaeochromocytoma Ureteric cancer Pleural mesothelioma Netherton's syndrome Myelofibrosis Small intestine leiomyosarcoma KBG syndrome Systemic lupus erythematosus More trials…

    Learn about Rare Diseases

    Rhabdomyosarcoma recurrent – Basic Information Pelizaeus-Merzbacher disease – Trials in Disease Tuberous sclerosis complex – Diagnostics Short-bowel syndrome – Basic Information Indolent systemic mastocytosis – Treatment Krabbe’s disease – Treatment Sjogren’s syndrome – Diagnostics Anaplastic thyroid cancer Haemophilia A with anti factor VIII Haemophilia A with anti factor VIII – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Thiamazole Pimavanserin Tartrate Azd5863 Perampanel Teriflunomide Insulin Icodec Tecovirimat Human Coagulation Factor Ii Bosentan Nitric Oxide Moxifloxacin Hepatitis B Surface Antigen Tilmanocept Pirfenidone Gtaexs617 Litenimod Sodium SECRETIN SYNTHETIC HUMAN Avb-101 Isavuconazonium Sulfate Fluorometholone More therapies…

    Learn about Your Condition

    Tendon disorder Prodromal Alzheimer's disease Peritoneal cancer index Laryngeal cancer B-cell lymphoma refractory Acute myocardial infarction MELAS syndrome Vaginal haemorrhage Sleep disorder Aortic disorder Autoimmune disorder Mechanical ventilation Cervix carcinoma stage II Leiomyosarcoma metastatic Mantle cell lymphoma stage IV More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma refractory

  • Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Bortezomib
    • Carfilzomib
    • Dexamethasone
    Belgium Croatia Czechia Denmark Finland France +10

  • Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Mezigdomide
    • Bortezomib
    • Dexamethasone
    Austria Belgium Czechia Finland France Germany +7

  • Study of isatuximab, evorpacept and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Isatuximab
    • Dexamethasone
    France Germany Greece Italy Norway Portugal

  • Study of isatuximab, pomalidomide and dexamethasone combination for patients with relapsed or refractory multiple myeloma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Isatuximab
    • Dexamethasone
    • Pomalidomide
    France Germany Greece Italy Norway Portugal

  • Study of isatuximab, belumosudil and dexamethasone combination treatment for patients with relapsed or refractory multiple myeloma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Belumosudil Mesilate
    • Isatuximab
    • Dexamethasone
    France Germany Greece Italy Norway Portugal

  • Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • ARLOCABTAGENE AUTOLEUCEL
    • Fludarabine Phosphate
    • Carfilzomib
    Austria Belgium Czechia Denmark Finland France +11
Previous Page
1 2 3 4 … 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!